Q-omics provides the consensus-scored KLHL38 profile across patient tissues and cancer cell-line models. KLHL38 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, KLHL38 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, KLHL38 RNA expression shows 16,659 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and HNSC as cancer lineages where KLHL38 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLHL38 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLHL38 survival associations across molecular data types. KLHL38 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLHL38 RNA expression–survival associations across cancer types. High KLHL38 expression shows unfavorable associations in UVM, MESO, KIRP, CESC and COAD, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for KLHL38 RNA expression.
This table summarizes KLHL38 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for KLHL38. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLHL38 shows lower tumor expression in HNSC, UCEC and BLCA and higher tumor expression in BRCA, LIHC and KIRC. The HNSC box plot shows higher KLHL38 RNA expression in normal versus tumor tissue (log2 FC = −0.952, t-test p = .002).
This table shows molecular features associated with KLHL38 in patient tissues and cancer cell lines. In patient samples, KLHL38 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, KLHL38 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
